Evidence map›Paper›PMID 26902206›Full record

ArticleMolecular & cellular proteomics : MCP2016

Systematic Analysis of Intracellular-targeting Antimicrobial Peptides, Bactenecin 7, Hybrid of Pleurocidin and Dermaseptin, Proline-Arginine-rich Peptide, and Lactoferricin B, by Using Escherichia coli Proteome Microarrays.

Yu-Hsuan Ho, Pramod Shah, Yi-Wen Chen, Chien-Sheng Chen

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
3.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 72 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Biodegradable Polymers and Polymer Composites with Antibacterial Properties.International journal of molecular sciences · 2023
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yu-Hsuan HoFrom the ‡Graduate Institute of Systems Biology and Bioinformatics, National Central University, Jhongli 32001, Taiwan; §Department of Biomedical Science and Engineering, National Central University, Jhongli 32001, Taiwan.
Pramod ShahFrom the ‡Graduate Institute of Systems Biology and Bioinformatics, National Central University, Jhongli 32001, Taiwan; §Department of Biomedical Science and Engineering, National Central University, Jhongli 32001, Taiwan.
Yi-Wen ChenFrom the ‡Graduate Institute of Systems Biology and Bioinformatics, National Central University, Jhongli 32001, Taiwan; §Department of Biomedical Science and Engineering, National Central University, Jhongli 32001, Taiwan.
Chien-Sheng ChenFrom the ‡Graduate Institute of Systems Biology and Bioinformatics, National Central University, Jhongli 32001, Taiwan; §Department of Biomedical Science and Engineering, National Central University, Jhongli 32001, Taiwan cchen103@gmail.com.
National Central University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial peptides (AMPs) act either through membrane lysis or by attacking intracellular targets. Intracellular targeting AMPs are a resource for antimicrobial agent development. Several AMPs have been identified as intracellular targeting peptides; however, the intracellular targets of many of these peptides remain unknown. In the present study, we used an Escherichia coli proteome microarray to systematically identify the protein targets of three intracellular targeting AMPs: bactenecin 7 (Bac7), a hybrid of pleurocidin and dermaseptin (P-Der), and proline-arginine-rich peptide (PR-39). In addition, we also included the data of lactoferricin B (LfcinB) from our previous study for a more comprehensive analysis. We analyzed the unique protein hits of each AMP in the Kyoto Encyclopedia of Genes and Genomes. The results indicated that Bac7 targets purine metabolism and histidine kinase, LfcinB attacks the transcription-related activities and several cellular carbohydrate biosynthetic processes, P-Der affects several catabolic processes of small molecules, and PR-39 preferentially recognizes proteins involved in RNA- and folate-metabolism-related cellular processes. Moreover, both Bac7 and LfcinB target purine metabolism, whereas LfcinB and PR-39 target lipopolysaccharide biosynthesis. This suggested that LfcinB and Bac7 as well as LfcinB and PR-39 have a synergistic effect on antimicrobial activity, which was validated through antimicrobial assays. Furthermore, common hits of all four AMPs indicated that all of them target arginine decarboxylase, which is a crucial enzyme for Escherichia coli survival in extremely acidic environments. Thus, these AMPs may display greater inhibition to bacterial growth in extremely acidic environments. We have also confirmed this finding in bacterial growth inhibition assays. In conclusion, this comprehensive identification and systematic analysis of intracellular targeting AMPs reveals crucial insights into the intracellular mechanisms of the action of AMPs.

Indexed as

Anti-Infective AgentsAntimicrobial Cationic PeptidesCarboxy-LyasesEscherichia coliEscherichia coli ProteinsGene Expression Regulation, BacterialLactoferrinMetabolic Networks and PathwaysMicrobial Sensitivity TestsPeptides, CyclicProtein Array AnalysisProteomicsAnti-Infective AgentsAntimicrobial Cationic Peptidesarginine decarboxylasebactenecinCarboxy-LyasesEscherichia coli Proteinslactoferricin BLactoferrinPeptides, Cyclic

Identifiers

PMID26902206
PMCPMC5083092
OpenAlexW2275361191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.